Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/40259 |
Resumo: | Attention Deficit Hyperactivity Disorder (ADHD) is a neurological disorder that is associated with poor brain performance. Individuals with ADHD have dyslexia, a certain impulsiveness and difficulty concentrating, resulting in poor school development. Taking into account, about 2.5 million new cases are declared per year in Brazil, whether due to real necessity or mere mediocrity of the diagnosis. Lisdexamfetamine methylphenidate is the main representative of a new class of long-acting agents for the treatment of ADHD, in current scenarios it has been the drug traditionally used as first choice for the treatment of children and adolescents with ADHD. Therefore, the general objective of this study was to analyze the effects that lisdexamfetamine dimesylate has for individuals with ADHD. In the methodology, a literature review was carried out, including studies in Portuguese and published between 2017 and 2022. Data collection took place in PubMed, LILACS, Scielo and Google Scholar databases. In the results, the safety and efficacy of lisdexamfetamine dimesylate for patients with ADHD proved to be effective and positive. In the studies found, it was understood that this drug has as its mechanism of action the blockade of the reuptake of the neurotransmitter dopamine and the stimulus to its production and noradrenaline. This action is what makes the stimulant of this medicine effective. |
id |
UNIFEI_ae11f74ac5b6efaabe1e9489ca620789 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/40259 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature reviewSeguridad y eficacia del dimesilato de lisdexanfetamina en el trastorno por déficit de atención con hiperactividad: una revisión de la literaturaSegurança e eficácia do dimesilato de lisdexanfetamina em transtorno de déficit de atenção e hiperatividade: uma revisão literáriaDimesilato de lisdexanfetaminaDesorden de déficit de atenciónHiperactividadEficiencia.Dimesilato de LisdexanfetaminaTranstorno de déficit de atençãoHiperatividadeEficácia.Lisdexamfetamine dimesylateAttention deficit disorderHyperactivityEfficiency.Attention Deficit Hyperactivity Disorder (ADHD) is a neurological disorder that is associated with poor brain performance. Individuals with ADHD have dyslexia, a certain impulsiveness and difficulty concentrating, resulting in poor school development. Taking into account, about 2.5 million new cases are declared per year in Brazil, whether due to real necessity or mere mediocrity of the diagnosis. Lisdexamfetamine methylphenidate is the main representative of a new class of long-acting agents for the treatment of ADHD, in current scenarios it has been the drug traditionally used as first choice for the treatment of children and adolescents with ADHD. Therefore, the general objective of this study was to analyze the effects that lisdexamfetamine dimesylate has for individuals with ADHD. In the methodology, a literature review was carried out, including studies in Portuguese and published between 2017 and 2022. Data collection took place in PubMed, LILACS, Scielo and Google Scholar databases. In the results, the safety and efficacy of lisdexamfetamine dimesylate for patients with ADHD proved to be effective and positive. In the studies found, it was understood that this drug has as its mechanism of action the blockade of the reuptake of the neurotransmitter dopamine and the stimulus to its production and noradrenaline. This action is what makes the stimulant of this medicine effective.El Trastorno por Déficit de Atención con Hiperactividad (TDAH) es un trastorno neurológico que se asocia con un rendimiento cerebral deficiente. Las personas con TDAH presentan dislexia, cierta impulsividad y dificultad para concentrarse, lo que se traduce en un pobre desarrollo escolar. Teniendo en cuenta que cerca de 2,5 millones de nuevos casos son declarados por año en Brasil, ya sea por necesidad real o por mera mediocridad del diagnóstico. El metilfenidato de lisdexanfetamina es el principal representante de una nueva clase de agentes de acción prolongada para el tratamiento del TDAH, en los escenarios actuales ha sido el fármaco tradicionalmente utilizado como primera elección para el tratamiento de niños y adolescentes con TDAH. Por tanto, el objetivo general de este estudio fue analizar los efectos que tiene el dimesilato de lisdexanfetamina en personas con TDAH. En la metodología, se realizó una revisión de la literatura, incluyendo estudios en portugués y publicados entre 2017 y 2022. La recolección de datos se realizó en las bases de datos PubMed, LILACS, Scielo y Google Scholar. En los resultados, la seguridad y eficacia del dimesilato de lisdexanfetamina para pacientes con TDAH demostró ser efectiva y positiva. En los estudios encontrados se entendió que este fármaco tiene como mecanismo de acción el bloqueo de la recaptación del neurotransmisor dopamina y el estímulo a su producción y noradrenalina. Esta acción es la que hace que el estimulante de este medicamento sea efectivo.Transtorno do Déficit de Atenção com Hiperatividade (TDAH) é um distúrbio neurológico que está afiliado a um diferente desempenho do cérebro. Indivíduos com TDAH apresentam dislexia, uma certa impulsividade e dificuldade de concentração, acarretando num baixo desenvolvimento escolar. Levando em consideração, cerca de 2,5 milhões de novos casos são declarados por ano no Brasil, sendo eles por necessidade real ou mera mediocrização do diagnóstico. O Metilfenidato de Lisdexanfetamina é o principal representante de uma nova classe de agentes de ação prolongada para o tratamento de TDAH, nos cenários atuais tem sido a droga tradicionalmente utilizada em primeira escolha, para o tratamento de crianças e adolescentes com TDAH. Diante disso, o objetivo geral deste estudo foi analisar os efeitos que o dimesilato de lisdexanfetamina possui para os indivíduos portadores de TDAH. Na metodologia, foi realizada uma revisão da literatura onde foram incluídos estudos em língua portuguesa e publicados entre 2017 a 2022. A coleta de dados se deu nas bases de dados PubMed, LILACS, Scielo e Google Acadêmico. Nos resultados, a segurança e eficácia do dimesilato de lisdexanfetamina para pacientes com TDAH se mostrou eficaz e positiva. Nos estudos encontrados, entendeu-se que esse medicamento tem como mecanismo de ação o bloqueio da recaptação do neurotransmissor dopamina e o estímulo à produção dela e de noradrenalina. Essa ação é que torna efetivo o estimulante deste medicamento.Research, Society and Development2023-02-13info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/4025910.33448/rsd-v12i2.40259Research, Society and Development; Vol. 12 No. 2; e28412240259Research, Society and Development; Vol. 12 Núm. 2; e28412240259Research, Society and Development; v. 12 n. 2; e284122402592525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/40259/32963Copyright (c) 2023 Fernanda Duarte Maciel ; Maria Eduarda Fonseca; Jéssyka Viana Valadares Franco; João Paulo Silva Azeredo ; Allan Michael de Lima; Fernanda Viana de Almeida ; Fernanda Paim Braga da Silva ; Késia Castro de Aguiar ; Gustavo Soares Lobo; João Paulo de Jesus Soares Lealhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMaciel , Fernanda Duarte Fonseca, Maria EduardaFranco, Jéssyka Viana Valadares Azeredo , João Paulo Silva Lima, Allan Michael de Almeida , Fernanda Viana de Silva , Fernanda Paim Braga da Aguiar , Késia Castro de Lobo, Gustavo Soares Leal, João Paulo de Jesus Soares 2023-02-14T20:07:52Zoai:ojs.pkp.sfu.ca:article/40259Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2023-02-14T20:07:52Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review Seguridad y eficacia del dimesilato de lisdexanfetamina en el trastorno por déficit de atención con hiperactividad: una revisión de la literatura Segurança e eficácia do dimesilato de lisdexanfetamina em transtorno de déficit de atenção e hiperatividade: uma revisão literária |
title |
Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review |
spellingShingle |
Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review Maciel , Fernanda Duarte Dimesilato de lisdexanfetamina Desorden de déficit de atención Hiperactividad Eficiencia. Dimesilato de Lisdexanfetamina Transtorno de déficit de atenção Hiperatividade Eficácia. Lisdexamfetamine dimesylate Attention deficit disorder Hyperactivity Efficiency. |
title_short |
Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review |
title_full |
Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review |
title_fullStr |
Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review |
title_full_unstemmed |
Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review |
title_sort |
Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review |
author |
Maciel , Fernanda Duarte |
author_facet |
Maciel , Fernanda Duarte Fonseca, Maria Eduarda Franco, Jéssyka Viana Valadares Azeredo , João Paulo Silva Lima, Allan Michael de Almeida , Fernanda Viana de Silva , Fernanda Paim Braga da Aguiar , Késia Castro de Lobo, Gustavo Soares Leal, João Paulo de Jesus Soares |
author_role |
author |
author2 |
Fonseca, Maria Eduarda Franco, Jéssyka Viana Valadares Azeredo , João Paulo Silva Lima, Allan Michael de Almeida , Fernanda Viana de Silva , Fernanda Paim Braga da Aguiar , Késia Castro de Lobo, Gustavo Soares Leal, João Paulo de Jesus Soares |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Maciel , Fernanda Duarte Fonseca, Maria Eduarda Franco, Jéssyka Viana Valadares Azeredo , João Paulo Silva Lima, Allan Michael de Almeida , Fernanda Viana de Silva , Fernanda Paim Braga da Aguiar , Késia Castro de Lobo, Gustavo Soares Leal, João Paulo de Jesus Soares |
dc.subject.por.fl_str_mv |
Dimesilato de lisdexanfetamina Desorden de déficit de atención Hiperactividad Eficiencia. Dimesilato de Lisdexanfetamina Transtorno de déficit de atenção Hiperatividade Eficácia. Lisdexamfetamine dimesylate Attention deficit disorder Hyperactivity Efficiency. |
topic |
Dimesilato de lisdexanfetamina Desorden de déficit de atención Hiperactividad Eficiencia. Dimesilato de Lisdexanfetamina Transtorno de déficit de atenção Hiperatividade Eficácia. Lisdexamfetamine dimesylate Attention deficit disorder Hyperactivity Efficiency. |
description |
Attention Deficit Hyperactivity Disorder (ADHD) is a neurological disorder that is associated with poor brain performance. Individuals with ADHD have dyslexia, a certain impulsiveness and difficulty concentrating, resulting in poor school development. Taking into account, about 2.5 million new cases are declared per year in Brazil, whether due to real necessity or mere mediocrity of the diagnosis. Lisdexamfetamine methylphenidate is the main representative of a new class of long-acting agents for the treatment of ADHD, in current scenarios it has been the drug traditionally used as first choice for the treatment of children and adolescents with ADHD. Therefore, the general objective of this study was to analyze the effects that lisdexamfetamine dimesylate has for individuals with ADHD. In the methodology, a literature review was carried out, including studies in Portuguese and published between 2017 and 2022. Data collection took place in PubMed, LILACS, Scielo and Google Scholar databases. In the results, the safety and efficacy of lisdexamfetamine dimesylate for patients with ADHD proved to be effective and positive. In the studies found, it was understood that this drug has as its mechanism of action the blockade of the reuptake of the neurotransmitter dopamine and the stimulus to its production and noradrenaline. This action is what makes the stimulant of this medicine effective. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-02-13 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/40259 10.33448/rsd-v12i2.40259 |
url |
https://rsdjournal.org/index.php/rsd/article/view/40259 |
identifier_str_mv |
10.33448/rsd-v12i2.40259 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/40259/32963 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 12 No. 2; e28412240259 Research, Society and Development; Vol. 12 Núm. 2; e28412240259 Research, Society and Development; v. 12 n. 2; e28412240259 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052618385653760 |